All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
During the 25th Congress of the European Hematology Association (EHA), the MPN Hub spoke to Haifa Kathrin Al-Ali, University Hospital Halle (Saale), Halle (Saale), DE. We asked: Why should we target murine double minute 2 (MDM2) with the small molecule inhibitor KRT-232 in patients with myelofibrosis (MF)?
Approximately 50% of patients with MF discontinue treatment with Janus kinase (JAK) inhibitors within 3 years. Resistance to JAK inhibitors, such as ruxolitinib, is the primary reason for treatment termination, after which, patient prognosis is poor. Novel therapeutic approaches are therefore critical to improve patient survival in this setting. As a negative modulator of p53, MDM2 overexpression has been associated with malignancy.
KRT-232 is a potent, selective and, importantly, orally available MDM2 inhibitor, which may be successful in targeting malignant stem cells and hematopoietic cells. This interview provides insight into the phase IIa trial investigating KRT-232 for the treatment of patients with MF who have been previously treated with a JAK inhibitor.
Why should we target MDM2 with small molecule inhibitor KRT-232 in patients with MF?
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox